pharma news today glp-1 Roundup: 12 Massive Updates People using popular weight-loss drugs

A larger February 2025 study analyzing 37.1 million adults with diabetes across 14 databases found semaglutide users had more than 4 times greater risk of NAION compared to non-GLP-1 drugs, with an incidence rate ratio of 1.32

While less common, serious side effects and risks are possible and require medical attention

Some of the most well-known include: Semaglutide (Ozempic, Wegovy): Approved for both diabetes management and weight loss

Inform your healthcare provider if you experience neck swelling, hoarseness, difficulty swallowing, or shortness of breath

Liraglutide improves water maze learning and memory performance while reduces hyperphosphorylation of tau and neurofilaments in APP/PS1/tau triple transgenic mice